Gene therapy player Affinia aims to go public, hoping to raise big money in effort to remake AAVs
Nine months after Affinia Therapeutics raised $110 million in a Series B, the biotech has set its eyes on the Nasdaq.
The MA-based preclinical gene therapy biotech, which got $60 million in startup capital from New Enterprise Associates, F-Prime and Atlas in 2019, filed an S-1 with the SEC on Tuesday, announcing initial plans to go public and penciling in a $100 million raise. Affinia plans to list under the ticker $AFTX.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.